Cargando…

PARP Inhibitors in Combination with Radiotherapy: To Do or Not to Do?

SIMPLE SUMMARY: Despite the large use of inhibitors of Poly-ADP ribose polymerase (PARP-I), the feasibility and safety of their combination with radiotherapy (RT) are unclear. The combination may be particularly interesting in the oligometastatic setting in which patients may benefit from local RT d...

Descripción completa

Detalles Bibliográficos
Autores principales: Barcellini, Amelia, Loap, Pierre, Murata, Kazutoshi, Villa, Riccardo, Kirova, Youlia, Okonogi, Noriyuki, Orlandi, Ester
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8582502/
https://www.ncbi.nlm.nih.gov/pubmed/34771545
http://dx.doi.org/10.3390/cancers13215380
_version_ 1784597001554362368
author Barcellini, Amelia
Loap, Pierre
Murata, Kazutoshi
Villa, Riccardo
Kirova, Youlia
Okonogi, Noriyuki
Orlandi, Ester
author_facet Barcellini, Amelia
Loap, Pierre
Murata, Kazutoshi
Villa, Riccardo
Kirova, Youlia
Okonogi, Noriyuki
Orlandi, Ester
author_sort Barcellini, Amelia
collection PubMed
description SIMPLE SUMMARY: Despite the large use of inhibitors of Poly-ADP ribose polymerase (PARP-I), the feasibility and safety of their combination with radiotherapy (RT) are unclear. The combination may be particularly interesting in the oligometastatic setting in which patients may benefit from local RT during the treatment with PARP-I. The aim of the current review was to evaluate the outcome and the toxicity in patients with newly diagnosed or recurrent tumors treated with a combination of PARP-I and RT. A total of 12 clinical studies met the inclusion criteria and, despite the heterogeneity of the evaluated patient populations and tumor types, this review suggests that a combination approach is feasible even though the efficacy profile remains unclear. ABSTRACT: Background: Despite the large use of inhibitors of Poly-ADP ribose polymerase (PARP-I), the feasibility and safety of their combination with radiotherapy (RT) is unclear. Aim: We conducted a literature analysis with the aim to evaluate the efficacy and safety profile of a combination with RT and PARP-I. Method: The key issues for the current review were expressed in two questions according to the Population, Intervention, Control, Outcome (PICO) criteria: 1. What is the outcome and 2. What is the toxicity in patients treated with a combination of PARP-I and RT for a newly diagnosed or recurrent tumors? Results: A total of 12 clinical studies met the inclusion criteria including seven single-arm dose-escalation phase I studies, two phase II (two- and three-arms controlled trials) trials, one parallel-arm phase I study, and two phase I/II studies published between 2015 and 2021. RT was performed with photon beams and several schedules according to the clinical situation. The acute toxicity ≥ grade 3 ranged between 25% and >96%, which was divided into hematological or non-hematological adverse events. Conclusions: despite the heterogeneity of the evaluated patient populations and tumor types, and the limited number of the studies, this review suggests that a combination approach is feasible even though the efficacy profile remains unclear.
format Online
Article
Text
id pubmed-8582502
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-85825022021-11-12 PARP Inhibitors in Combination with Radiotherapy: To Do or Not to Do? Barcellini, Amelia Loap, Pierre Murata, Kazutoshi Villa, Riccardo Kirova, Youlia Okonogi, Noriyuki Orlandi, Ester Cancers (Basel) Review SIMPLE SUMMARY: Despite the large use of inhibitors of Poly-ADP ribose polymerase (PARP-I), the feasibility and safety of their combination with radiotherapy (RT) are unclear. The combination may be particularly interesting in the oligometastatic setting in which patients may benefit from local RT during the treatment with PARP-I. The aim of the current review was to evaluate the outcome and the toxicity in patients with newly diagnosed or recurrent tumors treated with a combination of PARP-I and RT. A total of 12 clinical studies met the inclusion criteria and, despite the heterogeneity of the evaluated patient populations and tumor types, this review suggests that a combination approach is feasible even though the efficacy profile remains unclear. ABSTRACT: Background: Despite the large use of inhibitors of Poly-ADP ribose polymerase (PARP-I), the feasibility and safety of their combination with radiotherapy (RT) is unclear. Aim: We conducted a literature analysis with the aim to evaluate the efficacy and safety profile of a combination with RT and PARP-I. Method: The key issues for the current review were expressed in two questions according to the Population, Intervention, Control, Outcome (PICO) criteria: 1. What is the outcome and 2. What is the toxicity in patients treated with a combination of PARP-I and RT for a newly diagnosed or recurrent tumors? Results: A total of 12 clinical studies met the inclusion criteria including seven single-arm dose-escalation phase I studies, two phase II (two- and three-arms controlled trials) trials, one parallel-arm phase I study, and two phase I/II studies published between 2015 and 2021. RT was performed with photon beams and several schedules according to the clinical situation. The acute toxicity ≥ grade 3 ranged between 25% and >96%, which was divided into hematological or non-hematological adverse events. Conclusions: despite the heterogeneity of the evaluated patient populations and tumor types, and the limited number of the studies, this review suggests that a combination approach is feasible even though the efficacy profile remains unclear. MDPI 2021-10-27 /pmc/articles/PMC8582502/ /pubmed/34771545 http://dx.doi.org/10.3390/cancers13215380 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Barcellini, Amelia
Loap, Pierre
Murata, Kazutoshi
Villa, Riccardo
Kirova, Youlia
Okonogi, Noriyuki
Orlandi, Ester
PARP Inhibitors in Combination with Radiotherapy: To Do or Not to Do?
title PARP Inhibitors in Combination with Radiotherapy: To Do or Not to Do?
title_full PARP Inhibitors in Combination with Radiotherapy: To Do or Not to Do?
title_fullStr PARP Inhibitors in Combination with Radiotherapy: To Do or Not to Do?
title_full_unstemmed PARP Inhibitors in Combination with Radiotherapy: To Do or Not to Do?
title_short PARP Inhibitors in Combination with Radiotherapy: To Do or Not to Do?
title_sort parp inhibitors in combination with radiotherapy: to do or not to do?
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8582502/
https://www.ncbi.nlm.nih.gov/pubmed/34771545
http://dx.doi.org/10.3390/cancers13215380
work_keys_str_mv AT barcelliniamelia parpinhibitorsincombinationwithradiotherapytodoornottodo
AT loappierre parpinhibitorsincombinationwithradiotherapytodoornottodo
AT muratakazutoshi parpinhibitorsincombinationwithradiotherapytodoornottodo
AT villariccardo parpinhibitorsincombinationwithradiotherapytodoornottodo
AT kirovayoulia parpinhibitorsincombinationwithradiotherapytodoornottodo
AT okonoginoriyuki parpinhibitorsincombinationwithradiotherapytodoornottodo
AT orlandiester parpinhibitorsincombinationwithradiotherapytodoornottodo